Tereza R. Glechyan

Tereza R. Glechyan

Auto-generated profile, based on publicly available information

Tereza R. Glechyan

Kuban State Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
PGPavel A. Galenko-Yaroshevsky
Pavel A. Galenko-Yaroshevsky
OSOlga V. Shelemekh
Olga V. Shelemekh
VPViktor L. Popkov
Viktor L. Popkov
AZAndrey V. Zadorozhniy
Andrey V. Zadorozhniy
INIrina B. Nektarevskaya
Irina B. Nektarevskaya
NKNikolay E. Korovaykin
Nikolay E. Korovaykin
Introduction: Although nonsteroidal anti-inflammatory drugs (NSAIDs) have a clear therapeutic benefit, they can also have serious side effects. The most serious of these is the ulcerogenic effect, which can result in a decline in the quality of life or even death. This calls for the search for and creation of novel compounds with potent anti-inflammatory properties that do not have adverse effects on the digestive system. The aim of the study was to investigate the anti-inflammatory, analgesic, ulcerogenic and anti-ulcerogenic activities of N-isopropenylimidazole zinc complex derivative. Materials and Methods: Experiments in rats and mice were used to determine the median lethal dose LD50 for N-isopropenylimidazole zinc complex derivative (laboratory name Pilim-1). Experimental models of acute exudative inflammation and chronic proliferative inflammation were used. In the first case, the inflammation was induced by sub-plantar injection of carrageenan and a complete Freund’s adjuvant into the hind paw of rats. In the second case, the inflammation was induced by the implantation of a sterile cotton pellet (“cotton pellet–induced granuloma”) under the skin of rats. Acute and tonic pain, visceral, and somatic deep pain were simulated using the formalin test in rats and the acetic acid-induced writhing test in mice, respectively. The ulcerogenic and anti-ulcerogenic effects of Pilim-1 were studied in rat experiments. Pilim-1 and the reference drugs diclofenac, indomethacin and famotidine were administered intragastrically. Results and Discussion: Pilim-1 showed marked anti-inflammatory and analgesic effects, demonstrated less toxicity than diclofenac and indomethacin, while its activity is comparable to diclofenac and superior to indomethacin. Its therapeutic index is higher than that of indomethacin and diclofenac and, in contrast, it essentially has no ulcerogenic effect and exhibits stronger anti-ulcerogenic activity than famotidine. It appears that the anti-inflammatory, analgesic, and gastroprotective properties of Pilim-1 are largely due to its antioxidant and antihypoxic properties, its inhibitory effects on cyclooxygenase and 5-lipoxygenase, and the presence of imidazole and zinc in its structure, both of which have a wide range of biological activity. Conclusion: Pilim-1 can be recommended for further preclinical studies due to its relatively low (practically absent) ulcerative activity, strong anti-inflammatory, analgesic, and anti-ulcerative effects, greater therapeutic index, and less acute toxicity in comparison with diclofenac and indomethacin.

18 July 2024 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
PGPavel A. Galenko-Yaroshevsky
Pavel A. Galenko-Yaroshevsky
ITIvan Y Torshin
Ivan Y Torshin
AGAndrey N. Gromov
Andrey N. Gromov
IRIvan A. Reyer
Ivan A. Reyer
OGOlga Gromova
Olga Gromova
AZAnait Zelenskaya
Anait Zelenskaya
Introduction: For effective and safe pharmacotherapy of pain, it is important to evaluate the mechanisms and spectrum of action of non-steroidal anti-inflammatory drugs (NSAIDs), including their effect on the proteom, central effect, as well as pain relieving and anti-inflammatory effects. The aim of the study was to evaluate the complex of differences between the promising candidate-molecule of indole derivative SV-1010 and the well-known NSAIDs. Materials and Methods: Chemoproteomic moduling of pharmacological effects of SV-1010 and NSAID diclofenac, nimesulide and ketorolac on the rat proteom by means of topological analysis of chemographs. Results: The significant differences in the effects of the studied molecules were found for 820 proteins of the rat proteom. SV-1010, to a lesser degree than the other molecules, can inhibit dopamine D1- and D2-type receptors and, at the same time, stimulate the release of dopamine in the neostriatum (EC50 = 27 nM). SV-1010, to a greater extent than the other molecules, can inhibit the GABA conveyor (EC50 = 65 nM) and the NMDA receptors Grin1/Grin2b (IC50 175 nM). SV-1010 can activate Cannabinoid CB2 receptors, inhibit enzymes of leukotriene biosynthesis, CC receptors of pro-inflammatory chemokines and leukotrienes. Conclusion: The chemoreactomic and chemoproteomic profiling of SV-1010 indicated its potential central effect through dopaminergic and GABA-neurotransmission and additional anti-inflammatory mechanisms, which can help increase pain-relieving effects.

5 November 2024 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
PGPavel A. Galenko-Yaroshevsky
Pavel A. Galenko-Yaroshevsky
ITIvan Y Torshin
Ivan Y Torshin
AGA. N. Gromov
A. N. Gromov
OGOlga Gromova
Olga Gromova
KSKonstantin Suzdalev
Konstantin Suzdalev
EME.M. I. Muhammad
E.M. I. Muhammad
Background. To plan effective and safe pharmacotherapy for inflammation and pain, it is important to evaluate the mechanisms and spectrum of action of nonsteroidal anti-inflammatory drugs (NSAIDs), including their effects on human proteome.Objective: to identify and evaluate the most significant specific differences of candidate molecule RRS-1 (N-{(Z)-2-(1-methyl-1H-indol-3-yl)1-[(propylamino)carbonyl]vinyl}benzamide) from other NSAIDs through differential chemoreactome analysis.Material and methods. Chemoproteomic modeling of pharmacological effects of RRS-1 molecule and a number of well-known NSAIDs (diclofenac, nimesulide, ketorolac) on human proteome was carried out on the basis of numerical prediction algorithms over the space of heterogeneous feature descriptions, developed in the topological approach to recognition by Yu.I. Zhuravlev and K.V. Rudakov scientific school.Results. Significant differences in the effects of the studied molecules were found for 1232 proteins of human proteome. The features of assessing interactions of the studied molecules with 47 target proteins, which most distinguished the effects of RRS-1 molecule from all others were identified. RRS-1 could activate adenosine and dopamine receptors, cannabinoid receptor 2 and GABAA receptor to a greater extent than other molecules. Activation of these receptors corresponded to anti-inflammatory, anti-nociceptive and neuroprotective effects. RRS-1 could preferably inhibit a number of pro-inflammatory proteins, receptor bradykinin 1, metabotropic glutamate receptor 5, matrix metalloproteinases 8, 9, 12, and blood coagulation factor X. Additionally, RRS-1 molecule showed preferable inhibition of a number of kinases targeted in antitumor and anti-inflammatory therapy. RRS-1, less than other studied molecules, interacted with the receptors of vitamin D3, thyroid hormone, acetylcholine, cannabinoids and opioids, orexin, and various metabolic enzymes, which is important in assessment of the safety of using drugs based on this molecule. RRS-1 characteristically exhibited a moderate profile of antivitamin action: the total score of vitamin and mineral loss (7.4±3.7) was significantly less in comparison to diclofenac (11.7±4.5) and was actually on the same level as nimesulide (6.9±3.7) and ketorolac (6.7±3.6).Conclusion. Chemoreactomic and chemoproteomic profiling of RRS-1 candidate molecule provided pre-experimental assessments of its efficacy and safety through modeling interactions with the human proteome.

22 July 2024 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
LSLiliya L. Shamal
Liliya L. Shamal
OSOlga V. Shelemekh
Olga V. Shelemekh
RMRoman Murashko
Roman Murashko
TGTereza R. Glechyan
Tereza R. Glechyan
PGPavel A. Galenko-Yaroshevsky
Pavel A. Galenko-Yaroshevsky
Issues of the effectiveness and safety of drugs remain relevant and controversial. The benefits and risks of drug therapy are two facets of one whole, called pharmacotherapy, which can have undesirable side and even negatively outweigh the benefits. The effectiveness and safety of drugs must be studied comprehensively because new effects of drugs may be discovered and new mechanisms for unregistered indications may be revealed. Moreover, a deep understanding of adverse drug reactions will allow for the accurate prescription of drugs and proper medical supervision of therapy. Nonsteroidal anti-inflammatory drugs are over-the-counter drugs perceived by patients as safe and do not require a doctor’s prescription, which can cause dangerous drug reactions, particularly when used uncontrollably. The review presents literature data from studies on the effectiveness of nonsteroidal anti-inflammatory drugs and current data on new therapeutic effects of individual drugs, risks of adverse reactions, their mechanisms, and treatment methods.

24 November 2025 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
PGPavel A. Galenko-Yaroshevsky
Pavel A. Galenko-Yaroshevsky
AZAnait Zelenskaya
Anait Zelenskaya
KSKonstantin Suzdalev
Konstantin Suzdalev
ECElena N. Chuyan
Elena N. Chuyan
MRMarina Yu. Ravaeva
Marina Yu. Ravaeva
SKSergey Kozlov
Sergey Kozlov
Introduction: Various analgesics, primarily nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, are used to relieve pain. On the account that opioids can cause respiratory depression, psychological and physical dependence, as well as addiction, and NSAIDs can cause gastro- and enteropathy, nephrotoxicity, bronchospasm, bleeding, and cardiovascular dysfunction, the search for new molecules exerting an analgesic effect through other cellular targets is relevant. The aim of this study was to evaluate the analgesic effect of a new imidazo[1,2-a]indole derivative in various pain models and its effect on TRPV1 and κ-opioid receptors. Materials and Methods. The median lethal dose (LD50) of the imidazo[1,2-a]indole derivative (lab code SV-1010) was determined in experiments on mice and rats. The analgesic effect of SV-1010 was studied by means of the hot plate test (in mice), tail-flick test (in rats), paw pressure test (in rats), abdominal constriction test (in mice), formalin test (in rats), and neuropathic pain test (in rats). In addition, the effect of SV-1010 on TRPV1 ion channels was examined (in a Chinese hamster ovary cell line with an induced expression of a rat TRPV1 channel), and the potential for κ-opioid receptor activation was tested (by means of molecular docking). SV-1010 and the reference drugs diclofenac, indomethacin, ketorolac, and pregabalin were administered intragastrically. Results and Discussion: SV-1010 is less toxic than diclofenac, indomethacin, and ketorolac, exhibits a pronounced analgesic effect, but exceeds diclofenac, indomethacin, ketorolac, and pregabalin by the potency and therapeutic index. The treatment sites for SV-1010 to exert its analgesic effect are the supraspinal, supraspinal + peripheral, spinal, and peripheral levels of pain sensitivity. Of note is the high selectivity of SV-1010 to blocking TRPV1 ion channel and activating κ-opioid receptors. Conclusion: Significantly lower acute toxicity (when compared to such of diclofenac, indomethacin, and ketorolac), high analgesic activity, and a wider therapeutic index (when compared to such of diclofenac, indomethacin, ketorolac, and pregabalin) make SV-1010 promising for further preclinical study.